CN110418785A - 噻奈普汀草酸盐和多晶型 - Google Patents

噻奈普汀草酸盐和多晶型 Download PDF

Info

Publication number
CN110418785A
CN110418785A CN201780085697.9A CN201780085697A CN110418785A CN 110418785 A CN110418785 A CN 110418785A CN 201780085697 A CN201780085697 A CN 201780085697A CN 110418785 A CN110418785 A CN 110418785A
Authority
CN
China
Prior art keywords
tianeptine
crystalline
monooxalate
hemioxalate
oxalate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780085697.9A
Other languages
English (en)
Chinese (zh)
Inventor
S·L·吉亚弗雷达
E·摩德纳
S·发布洛尼
M·驰亚鲁希
M·T·埃德加
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tonix Pharma Holdings Ltd
Original Assignee
Tonix Pharma Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Holdings Ltd filed Critical Tonix Pharma Holdings Ltd
Publication of CN110418785A publication Critical patent/CN110418785A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
CN201780085697.9A 2016-12-28 2017-12-28 噻奈普汀草酸盐和多晶型 Pending CN110418785A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662439533P 2016-12-28 2016-12-28
US62/439,533 2016-12-28
PCT/IB2017/001709 WO2018122606A1 (en) 2016-12-28 2017-12-28 Tianeptine oxalate salts and polymorphs

Publications (1)

Publication Number Publication Date
CN110418785A true CN110418785A (zh) 2019-11-05

Family

ID=61283255

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780085697.9A Pending CN110418785A (zh) 2016-12-28 2017-12-28 噻奈普汀草酸盐和多晶型

Country Status (13)

Country Link
US (2) US10449203B2 (enExample)
EP (1) EP3562812A1 (enExample)
JP (2) JP2020503330A (enExample)
CN (1) CN110418785A (enExample)
AU (1) AU2017385958B2 (enExample)
BR (1) BR112019013244A2 (enExample)
CA (1) CA3048324A1 (enExample)
IL (1) IL267708A (enExample)
MX (1) MX2019007891A (enExample)
MY (1) MY199385A (enExample)
NZ (1) NZ754797A (enExample)
WO (1) WO2018122606A1 (enExample)
ZA (1) ZA201904185B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ754797A (en) * 2016-12-28 2022-05-27 Tonix Pharma Holdings Ltd Tianeptine oxalate salts and polymorphs
US20240165126A1 (en) 2021-03-15 2024-05-23 Tonix Pharmaceuticals Holding Corp. Tianeptine oxalate and naloxone combination for the treatment of major depressive disorder
CN117769540A (zh) * 2021-05-11 2024-03-26 亚士德制药公司 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2635461A1 (fr) * 1988-08-18 1990-02-23 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
WO2010051239A1 (en) * 2008-10-31 2010-05-06 Transform Pharmaceuticals, Inc. Tianeptine sulfate salt forms and methods of making and using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3758528A (en) * 1970-03-13 1973-09-11 Science Union & Cie Tricyclic compounds
US5405842A (en) 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
FR2791891A1 (fr) 1999-04-07 2000-10-13 Adir Utilisation de la tianeptine pour l'obtention de medicaments destines au traitement des pathologies de la neurodegenerescence
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
NZ754797A (en) * 2016-12-28 2022-05-27 Tonix Pharma Holdings Ltd Tianeptine oxalate salts and polymorphs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2635461A1 (fr) * 1988-08-18 1990-02-23 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
WO2010051239A1 (en) * 2008-10-31 2010-05-06 Transform Pharmaceuticals, Inc. Tianeptine sulfate salt forms and methods of making and using the same

Also Published As

Publication number Publication date
US10449203B2 (en) 2019-10-22
AU2017385958B2 (en) 2021-12-02
MY199385A (en) 2023-10-25
US10946027B2 (en) 2021-03-16
WO2018122606A1 (en) 2018-07-05
US20200276208A1 (en) 2020-09-03
JP2023001340A (ja) 2023-01-04
NZ754797A (en) 2022-05-27
EP3562812A1 (en) 2019-11-06
ZA201904185B (en) 2021-10-27
AU2017385958A1 (en) 2019-07-11
IL267708A (en) 2019-08-29
US20180338984A1 (en) 2018-11-29
MX2019007891A (es) 2019-12-16
CA3048324A1 (en) 2018-07-05
JP2020503330A (ja) 2020-01-30
BR112019013244A2 (pt) 2019-12-24

Similar Documents

Publication Publication Date Title
JP2023001340A (ja) チアネプチンシュウ酸塩および多形
JP2022530812A (ja) Ｗｅｅ１阻害剤化合物の結晶形及びその応用
JP2022528747A (ja) Ｆａｋ阻害剤の塩及び結晶形態
JP5899214B2 (ja) ４−［−２−［［５−メチル−１−（２−ナフタレニル）−１ｈ−ピラゾール−３−イル］オキシ］エチル］モルホリン塩酸塩の固体形態
CN102753155A (zh) 4-[-2-[[5-甲基-1-(2-萘基)-1h-吡唑-3-基]氧基]乙基]吗啉盐酸盐多晶型体和溶剂化物
WO2016091221A1 (zh) 吡咯并[2,3-d]嘧啶化合物的盐及盐的新晶型
JP2012517462A (ja) トリアゾロ［４，３−ｂ］ピリダジン誘導体および前立腺癌のためのそれらの使用
CN104356072A (zh) 5-氟尿嘧啶药物共晶及其制备方法
WO2016124149A1 (zh) 一种治疗前列腺癌的抗雄激素类药物的新晶型及其制备方法
JP2024544724A (ja) （Ｒ）－１－（１－アクリロイルピペリジン－３－イル）－４－アミノ－３－（４－フェノキシフェニル）－１Ｈ－イミダゾ［４，５－ｃ］ピリジン－２（３Ｈ）－オン及びその塩の結晶形態
TW201144319A (en) Salt of fused heterocyclic derivative and crystal thereof
WO2017107972A1 (zh) 一种选择性s1p1受体激动剂的新晶型及其制备方法
JP2023553021A (ja) ピロロピリミジン系化合物の塩、その結晶及びその使用
BR112013007073B1 (pt) Derivados do cromeno; composição farmacêutica; utilização de um composto da fórmula i e processo de preparação de um composto da fórmula i
JP2020505391A (ja) ウイルスタンパク質阻害薬ｖｘ−７８７の結晶形及びその製造方法並びに用途
HK40016628A (zh) 噻奈普汀草酸盐和多晶型
EP3917931A1 (en) Solid state forms of oclacitinib maleate
WO2023137035A1 (en) Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
WO2022017208A1 (zh) 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物
CN117510490A (zh) 一种稠合氮杂萘烷类衍生物的晶型及其制备方法
WO2025237212A1 (zh) 一种嘧啶衍生物葡甲胺盐及其晶型
CN101175758B (zh) N-[1-(2-乙氧基乙基)-5-(N-乙基-N-甲基氨基)-7-(4-甲基吡啶-2-基-氨基)-1H-吡唑并[4,3-d]嘧啶-3-羰基]甲磺酰胺的无水结晶形式
CN112174895A (zh) 一种雄性激素受体抑制剂的晶型及其制备方法
JP2021520363A (ja) 結晶形態のピモジビル塩酸塩半水和物を調製するための等温反応性結晶化方法
CN117624138A (zh) 一种氧杂螺环类衍生物的可药用盐、晶型及制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40016628

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20191105

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40016628

Country of ref document: HK